Header Logo

Connection

VIVEK SUBBIAH to MAP Kinase Kinase Kinases

Back to Details
This is a "connection" page, showing publications VIVEK SUBBIAH has written about MAP Kinase Kinase Kinases.
VIVEK SUBBIAH
Connection Strength
0.035
MAP Kinase Kinase Kinases
  1. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer. 2017 05 23; 116(11):1402-1407.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.